Acute Kidney Injury Among Children Likely Associated with Diethylene Glycol–Contaminated Medications — The Gambia, June–September 2022

Parsa Bastani, PhD1,2; Anna Jammeh, MD3,4; Frederica Lamar, PhD1,2; Jason H. Malenfant, MD1,5; Peter Adewuyi, MD6,7; Alyson M. Cavanaugh, PhD8; Kimberly Calloway, DVM1,8; Carolyn Crisp, PhD1,9; Nuha Fofana, MPhil3,10; T. Christy Hallett, MD9; Amadou Jallow, MSPH3,4; Uzoamaka Muoneke, MD11,12; Momodou Nyassi, MD3; Jerry Thomas, MD13; Alyssa Troeschel, PhD1,9; Ellen Yard, PhD2; Michael Yeh, MD9; Mustapha Bittaye, MD3 (View author affiliations)

View suggested citation


What is already known about this topic?

Diethylene glycol (DEG)–contaminated medications present a global health threat, especially in low-income countries.

What is added by this report?

A large cluster of acute kidney injury cases affecting children in The Gambia in 2022 was associated with case fatality rates >80%. The implicated syrup-based pediatric medications that had been administered to patients were imported from a single Indian manufacturer. This is one of the first documented DEG outbreaks in which contaminated medications were imported rather than being domestically manufactured.

What are the implications for public health practice?

DEG mass poisonings continue to occur worldwide, especially in low-resource settings. Strengthened international pharmaceutical regulatory structures and event-based surveillance systems can help prevent DEG-associated large-scale poisoning events.

Article Metrics

Views equals page views plus PDF downloads

The figure is a photo of two people looking at paperwork overlaid on an illustration of a map. The text reads, “Public Health in Action: In The Gambia during 2022, 78 children developed kidney failure; 66 died. An international team identified imported contaminated medicine as the source and took immediate action.”

On July 26, 2022, a pediatric nephrologist alerted The Gambia’s Ministry of Health (MoH) to a cluster of cases of acute kidney injury (AKI) among young children at the country’s sole teaching hospital, and on August 23, 2022, MoH requested assistance from CDC. CDC epidemiologists arrived in The Gambia, a West African country, on September 16 to assist MoH in characterizing the illness, describing the epidemiology, and identifying potential causal factors and their sources. Investigators reviewed medical records and interviewed caregivers to characterize patients’ symptoms and identify exposures. The preliminary investigation suggested that various contaminated syrup-based children’s medications contributed to the AKI outbreak. During the investigation, MoH recalled implicated medications from a single international manufacturer. Continued efforts to strengthen pharmaceutical quality control and event-based public health surveillance are needed to help prevent future medication-related outbreaks.

Investigation and Results

In July 2022, a pediatric nephrologist at the Edward Francis Small Teaching Hospital in The Gambia’s capital city of Banjul alerted MoH to a cluster of AKI cases among children. Data on AKI incidence are not routinely collected in The Gambia; thus, the baseline AKI rate was unknown. However, the treating nephrologist expressed concern that the number of cases and deaths were well above baseline: through August 12, a total of 30 pediatric deaths among 37 AKI cases had been reported from facilities throughout the country (case fatality rate = 81%). In response to a request for assistance, a multidisciplinary CDC team, including an epidemiologist, an anthropologist, an infectious disease physician, and an environmental health scientist, arrived on September 16 to assist the Field Epidemiology Training Program (FETP) and MoH in characterizing the illness and identifying exposures. MoH collaborated separately with the World Health Organization (WHO) to test medications that might have been used by patients.

Active surveillance was conducted through reoccurring communication with the teaching hospital and other regional hospitals, inquiring about admissions of pediatric patients with kidney failure. As of September 29, 2022, MoH had identified 78 clinically suspected AKI cases. Among these patients, 66 (85%) had died. Most patients (75%) were aged <2 years, and 60% were male. Cases were reported from six of the country’s seven health regions.* Among the 78 cases reported to MoH, symptom onset date was available for 67 (86%) (Figure).

CDC, MoH, and FETP investigators developed a standardized case report form to gather data about pediatric patients with AKI identified by MoH. Data collection consisted of a review of the patient’s medical records and caregiver interview data. For this investigation, a confirmed case of pediatric AKI was defined as anuria (no urine output) of unknown etiology in a child aged ≤8 years, persisting for ≥24 hours, during June 21–September 29, 2022. June 21 was chosen as the start date because medications suspected to have possibly caused the AKI outbreak had been imported into the country on June 21. Investigators first reviewed the medical records of 52 (67%) of the 78 MoH-identified patients with suspected AKI who were treated by the teaching hospital. Next, interviews with at least one caregiver of each of 27 patients were conducted by investigators in local languages, including the caregivers of 20 patients whose children’s hospital medical records were reviewed and seven patients whose medical records could not be located. Investigators selected a convenience sample of caregivers for interview based on their location of residence. Because of resource limitations and reluctance on the part of some caregivers to be interviewed, not all medical records could be located, and not all invited caregivers participated. In addition, interview data were collected in only two of the six health regions (Western Regions 1 and 2). This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy.

Caregivers were asked about the child’s recent medical history, including disease course, experiences with the health care system, and possible exposures, including medications, foods, and experience of flooding, among others. All participating caregivers were interviewed in their homes. All four (15%) living patients whose caregivers were interviewed had been discharged at the time of interview. Among patients who had died, the mean interval between date of death and date caregivers were contacted for interview was 33 days. Information from medical records and interviews was used to determine whether patients on the MoH line list met the confirmed case definition. After data from the 27 caregiver interviews and 52 medical record reviews were combined, 59 case report forms were completed, representing 76% of the 78 cases reported to MoH, and 88% of the 67 patients with a symptom onset date. Among these 59 patients, 56 (95%) met the confirmed case definition and were included in the analysis.§

Among the 56 included patients, more than one half (54%) experienced fever as their first signs or symptoms, and 50% experienced vomiting (Table 1). Approximately one third (34%) had diarrhea or loose stool as the first symptom. During the course of illness, all patients experienced anuria and fever, 95% experienced vomiting, and 73% experienced diarrhea. Nearly one half (48%) experienced anorexia or reduced feeding. The median interval from symptom onset to anuria was 5 days (IQR = 2–7 days); among the 26 patients who died, the median interval from onset of anuria to death was 6 days (IQR = 3–7 days).

Abnormal laboratory test results were received by 66%–100% of patients, including impaired renal and liver function, thrombocytosis, and mild to moderate anemia (Table 2). Fourteen patients underwent peritoneal dialysis, and one patient underwent hemodialysis; all 15 patients who received dialysis died.

Among the 26 patients with a caregiver interview, 100% of caregivers reported that the child consumed a prescription or over-the-counter syrup-based medication (including paracetamol, known in the United States as acetaminophen, commonly administered for fever) before the onset of anuria. Twelve patients (47%) had consumed four or more medications before being hospitalized. Although many caregivers were unable to recall the names of medications that they administered to their children, caregivers of 14 (54%) of these 26 patients identified the manufacturer name of at least one medication administered to their child before inpatient hospitalization. A single international manufacturer that produced a syrup-based medication was reported in eight of 14 (57%) interviews in which caregivers identified the manufacturer name of at least one medication administered to their child before inpatient hospitalization.

Public Health Response

Preliminary reports from the treating physicians at the teaching hospital indicated that caregivers had administered paracetamol and promethazine to their children before their development of AKI. Based on this information, MoH advised the public to suspend use of all paracetamol and promethazine syrups on September 7, 2022, and September 16, 2022, respectively (Figure). The laboratory analysis of 23 medication samples conducted by MoH and WHO confirmed that four products from Maiden Pharmaceuticals Limited (Haryana, India) contained diethylene glycol (DEG) and ethylene glycol (EG). Based on records from The Gambia’s Medicines Control Agency, all medications that tested positive for DEG and EG were imported into The Gambia on June 21, 2022, shortly before the occurrence of the first AKI cases.

On October 4, 2022, MoH suspended the importation of all medications from this manufacturer and requested that health care providers stop prescribing, dispensing, and using medications produced by this manufacturer because of their possible contamination. On October 5, 2022, WHO issued a worldwide medical product alert for four syrup-based medications from Maiden Pharmaceuticals (1). In collaboration with WHO, UNICEF, ChildFund The Gambia, and The Gambia Red Cross Society, MoH supported a house-to-house recall and collection of all products from this manufacturer in addition to all paracetamol, promethazine, and cough syrups. In conjunction with the recall, MoH promoted awareness about the contaminated medications through messaging on radio, television, social media, and in places of worship. MoH also commenced ongoing pharmacy spot checks to ensure that products from this manufacturer were not being sold. Surveillance officers were trained in case definitions, case report forms, following up with patients discharged from hospitals, and conducting active case finding in the community.


This investigation strongly suggests that medications contaminated with DEG or EG imported into The Gambia led to this AKI cluster among children. AKI outbreaks associated with DEG-contaminated pharmaceutical products have been documented in Panama, Nigeria, India, and Haiti (25). Patients with DEG poisoning can experience a range of signs and symptoms, including altered mental status, headache, and gastrointestinal symptoms; however, the most consistent manifestation is AKI, characterized by oliguria (low urine output) or anuria, progressing over 1–3 days to renal failure (indicated by elevated serum creatinine and blood urea nitrogen) (6). In past DEG outbreaks, manufacturers have been suspected of substituting DEG in the place of more expensive, pharmaceutical-grade solvents (3,7). Medication testing supported contaminated medical syrups as the etiology of this cluster of AKI cases (1).

Further support for a toxic etiology includes the wide geographic distribution of cases in the country (six of seven health regions), a common pharmaceutical manufacturer of medications reported to have been used by many patients, and a low rate of intrahousehold spread. This intoxication appears to have only affected children, likely because medications in syrup form are most commonly used for children in The Gambia.

Factors that might have led to poor caregiver recall regarding medications administered to their children include the assumption by caregivers that medications would not harm their children, difficulty of parents of children who had died recalling administered medications owing to the interval between patients’ deaths and the investigation, and the possibility of reduced reporting following the issuing of health alerts by MoH.

This likely poisoning event highlights the potential public health risks posed by the inadequate quality management of pharmaceutical exports. Among reports of AKI associated with DEG-contaminated medical products, this is the first in which DEG-contaminated medications were imported into a country, rather than being domestically manufactured. Inadequate regulatory structures make the sale of medications from international markets an especially high-risk activity in low-resource settings. Medications for export might be subject to less rigorous regulatory standards than those for domestic use (8). Simultaneously, low-resource countries might not have the human and financial resources to monitor and test imported drugs (8). In addition to improving pharmaceutical quality management, efforts should be made by MoH to strengthen event-based surveillance systems (9), which rely on unstructured information (e.g., reports, rumors, and other information) to detect unusual events that might signal an outbreak or other public health event. Event-based surveillance complements traditional reportable disease surveillance and has the potential to improve the ability to rapidly detect and respond to similar acute health events of unknown and unexpected etiologies. FETP-trained experts can provide valuable assistance in these and other efforts to help governments improve their capacities to detect and respond to outbreaks in the future.


World Health Organization; The Gambian Field Epidemiology Training Program; staff members at the Edward Francis Small Teaching Hospital, Banjul, The Gambia; CDC Organization of African Public Health Professionals; CDC Work Group on Health of Muslim Populations.

Corresponding author: Parsa Bastani,

1Epidemic Intelligence Service, CDC; 2Division of Global Health Protection, Center for Global Health, CDC; 3Ministry of Health, Banjul, The Gambia; 4Epidemiology Disease Control Unit, Ministry of Health, Banjul, The Gambia; 5Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 6The Gambian Field Epidemiology Training Program, Banjul, The Gambia; 7African Field Epidemiology Network, Kampala, Uganda; 8Division of Foodborne, Waterborne, and Environmental Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 9Division of Environmental Health Science and Practice, National Center for Environmental Health, CDC; 10Ghana Field Epidemiology and Laboratory Training Program, Accra, Ghana; 11Department of Pediatrics, University of Nigeria, Nsukka, Enugu, Nigeria; 12Department of Pediatrics, Edward Francis Small Teaching Hospital, Banjul, The Gambia; 13Division of Laboratory Sciences, National Center for Environmental Health, CDC.

All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

* Cases were reported from Western Region 1, Western Region 2, Upper River Region, North Bank West Region, Lower River Region, and Central River Region. Cases were not reported from the North Bank East Region.

45 C.F.R. part 46, 21 C.F.R. part 56; 42 U.S.C. Sect. 241(d); 5 U.S.C. Sect. 552a; 44 U.S.C. Sect. 3501 et seq.

§ The three patients who did not meet the case definition did not have documentation of anuria.


  1. World Health Organization. Substandard (contaminated) pediatric medicines identified in WHO region of Africa. Geneva, Switzerland: World Health Organization; 2022. Accessed November 11, 2022.
  2. Rentz ED, Lewis L, Mujica OJ, et al. Outbreak of acute renal failure in Panama in 2006: a case-control study. Bull World Health Organ 2008;86:749–56. PMID:18949211
  3. CDC. Fatal poisoning among young children from diethylene glycol-contaminated acetaminophen—Nigeria, 2008–2009. MMWR Morb Mortal Wkly Rep 2009;58:1345–7. PMID:20010509
  4. Singh J, Dutta AK, Khare S, et al. Diethylene glycol poisoning in Gurgaon, India, 1998. Bull World Health Organ 2001;79:88–95. PMID:11242827
  5. CDC. Fatalities associated with ingestion of diethylene glycol-contaminated glycerin used to manufacture acetaminophen syrup—Haiti, November 1995–June 1996. MMWR Morb Mortal Wkly Rep 1996;45:649–50. PMID:8769471
  6. Schep LJ, Slaughter RJ, Temple WA, Beasley DMG. Diethylene glycol poisoning. Clin Toxicol (Phila) 2009;47:525–35. PMID:19586352
  7. Schier JG, Rubin CS, Miller D, Barr D, McGeehin MA. Medication-associated diethylene glycol mass poisoning: a review and discussion on the origin of contamination. J Public Health Policy 2009;30:127–43. PMID:19597445
  8. Caudron JM, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 2008;13:1062–72. PMID:18631318
  9. Balajee SA, Salyer SJ, Greene-Cramer B, Sadek M, Mounts AW. The practice of event-based surveillance: concept and methods. Glob Secur Health Sci Policy 2021;6:1–9.
Return to your place in the textFIGURE. Date of first symptom onset for suspected cases of acute kidney injury of unknown etiology* among children (N = 67), critical events in the outbreak investigation, and public health recommendations — The Gambia, June 12–September 29, 2022
The figure is a bar graph showing the date of first symptom onset for suspected cases of acute kidney injury of unknown etiology among children, critical events in the outbreak investigation, and public health recommendations in The Gambia during June 12–September 29, 2022.

Abbreviations: AKI = acute kidney injury; MoH = The Gambia’s Ministry of Health.

* Baseline incidence of AKI not available. These data include cases from MoH Epidemiology and Disease Control Unit with reported date of initial symptom onset.

Among 78 cases reported to MoH, symptom onset date was available for 67 (86%) patients.

TABLE 1. Signs and symptoms reported at the onset of illness and at any time during illness, intervals between onset of symptoms and onset of anuria, intervals between onset of anuria and death, and available medical records or caregiver interviews among pediatric patients with acute kidney injury (N = 56)* — The Gambia, June–September 2022Return to your place in the text
Symptoms and intervals until anuria or death No. (%) No. of valid responses (median, [IQR])
First symptoms experienced
Fever 30 (54) NA
Vomiting 28 (50) NA
Diarrhea/Loose stool 19 (34) NA
Cough, runny nose, sneezing or unspecified cold symptom 7 (13) NA
Anuria 2 (4) NA
Anorexia 2 (4) NA
Other§ 5 (9) NA
Symptoms ever experienced
Anuria 56 (100) NA
Fever 56 (100) NA
Vomiting 53 (95) NA
Diarrhea/Loose stool 41 (73) NA
Reduced appetite/Decreased breastfeeding 27 (48) NA
Difficulty breathing 22 (39) NA
Cough, runny nose, sneezing or unspecified cold symptom 19 (34) NA
Rash 6 (11) NA
Abdominal pain 5 (9) NA
Convulsions/Seizures 4 (7) NA
Bloody diarrhea 1 (2) NA
Jaundice 0 (—) NA
Intervals from symptom onset to anuria (or death)
First symptoms experienced to anuria, days NA 31 (5 [2 to 7])
Vomiting onset to anuria, days NA 25 (2 [1 to 6])
Loss of appetite/Refusal to breastfeed onset to anuria, days NA 17 (1 [0 to 1])
Diarrhea onset to anuria, days NA 17 (4 [2 to 6])
Difficulty breathing onset to anuria, days NA 7 (0 [–3 to 1]**)
Onset of anuria to death, days NA 26 (5.5 [3 to 7])

Abbreviation: NA = not available.
* A confirmed case of pediatric acute kidney injury was defined as anuria (no urine output) of unknown etiology in a child aged ≤8 years, persisting for ≥24 hours, during June 21–September 29, 2022.
Percentages might sum to >100%, because multiple signs or symptoms could be reported for each patient.
§ Other reported symptoms included rash (one), headache (one), mouth ulcers (one), abdominal pain (one), and reduced urine output (one).
Responses were considered valid if patients had the signs or symptoms of interest and had onset dates for both variables involved in the interval. For example, the interval vomiting onset to anuria was only calculated among patients who experienced vomiting and anuria and had recorded onset dates available for both symptoms.
** A negative value for this interval indicates that anuria preceded breathing difficulties.

TABLE 2. Laboratory test results among patients with acute kidney injury following medication exposures — Edward Francis Small Teaching Hospital, The Gambia, June–September 2022Return to your place in the text
Laboratory test Normal reference range Median patient value (IQR) Abnormal test results
No./Total no. (%) Direction of abnormality
Hemoglobin 11.5–16.5 g/dL 10.3 (9.0–11.5) 31/38 (82) Low
Alanine transaminase 0–41 U/L 284.5 (135.0–473.0) 13/18 (72) High
Alkaline phosphatase 45–135 U/L 272.5 (212.0–350.0) 14/14 (100) High
Aspartate transferase 0–40 U/L 271.3 (176.5–610.5) 13/16 (81) High
Blood urea nitrogen 1.7–8.3 mmol/L 29.8 (16.0–41.0) 37/41 (90) High
Creatinine 44–123 μmol/L 711.0 (499.5–854.0) 34/38 (89) High
Platelets 130–400 x 109/L 511.0 (388.0–598.0) 23/35 (66) High

Suggested citation for this article: Bastani P, Jammeh A, Lamar F, et al. Acute Kidney Injury Among Children Likely Associated with Diethylene Glycol–Contaminated Medications — The Gambia, June–September 2022. MMWR Morb Mortal Wkly Rep 2023;72:217–222. DOI:

MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.

All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version ( and/or the original MMWR paper copy for printable versions of official text, figures, and tables.

Questions or messages regarding errors in formatting should be addressed to